Monsenso expands collaboration with Empano, a private provider of psychology and psychiatry services, signing a new contract to help citizens with stress return to work in the municipality of Slagelse.
Monsenso and Empano partnered up last year to help unemployed people get back to work faster. Together, Monsenso and Empano offer a solution for Danish municipalities to help unemployed people suffering from stress and depression return to work.
Following the successful implementation in the municipality of Guldborgssund, the services are now offered to more municipalities, starting in the municipality of Slagelse, Denmark.
Empano offers individual courses and group sessions to the employment sector in the municipalities and uses Monsenso’s digital health solution to collect self-reported data from service users to validate and demonstrate the program’s effectiveness.
The courses have a duration of 6-8 weeks each, after which new citizens are enrolled.
It is a preventative course that teaches strategies to reduce stress and promote mental health. Citizens are introduced to techniques that enable them to better cope with symptoms and challenges in everyday life and the job market, based on cognitive therapy, metacognitive therapy, and mindfulness.
“We are excited to expand our collaboration with Empano to help more people get back to work faster,” says CEO Thomas Lethenborg. “Mental health and unemployment are closely linked. While unemployment can cause stress which may have other negative consequences on people’s mental health, including depression, anxiety and lower self-esteem, a good mental health has shown to have a positive impact on employability, finding a job and staying in that job.”
Monsenso today announces that the board of Directors has decided to call for an Extraordinary General Meeting on January 29th, 2021, where two new members are proposed to be elected for the board.
Monsenso – a leading provider of mobile health solutions for mental health – plans to further strengthen the board by nominating two new professional board members with strong qualifications and competencies to support Monsenso in getting to the next level in the company’s growth journey: Peter Høngaard Andersen, formerly. Managing Director at Innovation Fund Denmark and VP at Lundbeck; Jacob Hahn Michelsen, SVP Private & Public at NNIT A/S.
Current board member Thomas Knudsen has offered to resign from his position on the board at the Extraordinary General Meeting. Thomas has supported Monsenso’s growth for several years from being a university research project spin-out to becoming an international publicly listed company on Nasdaq First North Growth Market Copenhagen. The board and the management of Monsenso would like to thank Thomas Knudsen for his outstanding work. His contributions have been essential in building up the product portfolio, securing the first rounds of financing, supporting the management and finally listing the company.
The new board is planning to constitute itself with Jukka Pertola as the Chairman and Jakob Bardram as the Vice Chairman until the next ordinary Annual General Meeting on April 14, 2021 where Jukka Pertola is expected to resign as the Chairman. Nomination of the new board members in January will help ensure an appropriate introduction, as well as a smooth transition and handover of responsibilities in the period leading up to the Annual General Meeting.
Jukka Pertola commented: ”Since I became a professional board member, I have been lucky to be invited to multiple boards of exciting companies, one of them being Monsenso. However, to address the good corporate governance requirements, I have decided to reduce my number of board positions and chairmanships. We have found an exceptionally strong pair of new board members, who can contribute to bringing Monsenso to the next level. Jacob Hahn Michelsen has extensive experience in pharma- and health-related software and IT, regulatory environment of medical applications and a valuable industry knowhow, while Peter Høngaard brings considerable experience from science and research, pharmaceuticals, neurology, intellectual property rights, innovation and funding.“
To read the Danish version, click here.
For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer